Swansea collaboration opens new doors for targeted therapies

ReNeuron Group Ltd is returning to South Wales with a new partnership at Swansea University’s Institute of Life Science (ILS), joining forces to explore next-generation exosome therapies. The collaboration will see ReNeuron relocate its operations to the ILS, combining the university’s specialist facilities and research expertise with ReNeuron’s know-how in exosome biology.

The project, led by Professors Steve Conlan and Deya Gonzalez from the Reproductive Biology and Gynaecological Oncology Research Group, will fund a full-time research associate to study how exosomes’ cellular origins influence their ability to target specific tissues. Building on earlier proof-of-concept work, the team aims to refine exosome delivery, helping therapies reach hard-to-access organs and cells.

Professor Deya Gonzalez said: “This partnership brings together academic insight and industrial expertise. By working closely with ReNeuron, we have an exciting opportunity to tackle one of medicine’s biggest challenges: delivering treatments exactly where they’re needed.”

Randolph Corteling, ReNeuron’s Managing Director and Chief Scientific Officer, added: “Our collaboration with Swansea University supports both long-term biotech growth in Wales and the progression of our research ambitions. Together, we can translate scientific innovation into therapies that make a real difference for patients.”

The partnership underscores Swansea’s growing role as a hub for life sciences, creating a bridge from laboratory research to potential clinical impact.

More information online